ATN-161
- Generic Name
- ATN-161
- Drug Type
- Small Molecule
- Chemical Formula
- C23H35N9O8S
- CAS Number
- 262438-43-7
- Unique Ingredient Identifier
- XW0H5LE42K
- Background
ATN-161 is a non-RGD based integrin binding peptide targeting alpha-5 beta-1 and alpha-v beta-3. It inhibits the migration and adhesion of particular integrins on activated endothelial cells that play a critical role in tumor angiogenesis. This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy. Since the expression of alpha(5)beta(1) integrin by cancer cells and the role of this molecule in tumor angiogenesis is similar across a range of different cancers, the therapeutic benefit of ATN-161 is expected to extend to a variety of cancers.
- Indication
Investigated for use/treatment in brain cancer and cancer/tumors (unspecified).
ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2012-05-02
- Target Recruit Count
- 82
- Registration Number
- NCT00352313
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
ATN-161 in Advanced Renal Cell Cancer
- Conditions
- Carcinoma, Renal Cell
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2007-12-06
- Lead Sponsor
- Attenuon
- Target Recruit Count
- 36
- Registration Number
- NCT00131651
- Locations
- 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸University of California San Francisco Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸University of California Irvine, Chao Family Comprehensive Cancer Center, Irvine, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.